Spruce Biosciences Inc (SPRB) Stock Price, Quote & News

Company Profile

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, includ...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 343 5986

Website: sprucebio.com

Address:

611 Gateway Boulevard, Suite 740, South San Francisco, United States

Jyoudoit Aug. 24 at 3:11 PM

$SPRB

0 · Reply

EDP554 Aug. 24 at 1:24 PM

$SPRB adding some more at open

0 · Reply

SannieVerraderlijk Aug. 24 at 12:51 PM

$SPRB Tiny float, 17% short, might run if it catches some volume

0 · Reply

SannieVerraderlijk Aug. 24 at 12:32 PM

$SPRB https://www.businesswire.com/news/home/20260824589114/en/Spruce-Biosciences-Announces-Positive-Pre-BLA-Meetings-with-FDA-and-Confirms-BLA-Submission-for-TA-ERT-on-Track-for-Q4-2026 BLA on track for Q4

0 · Reply

JeremyDanie Aug. 24 at 2:08 AM

$SPRB stop run…and go

0 · Reply

USAEquityResearch Aug. 22 at 6:45 AM

$SPRB 📊 USAEquityResearch ▼ 51.58 (-0.78%) Trend: Bullish 📈 RSI (14): 82.3 — overbought, extended, caution warranted MACD: bullish, above signal line and rising Volume: above average 📌 Key Levels Resistance: 52.96 | Support: 41.45 20-MA: 47.25 | 50-MA: 48.61 💼 Fundamentals Mkt Cap: $148.24M Fwd P/E: 6.4 FCF: $-20.65M (-7.18/sh) Total Debt: $7.67M D/E: 9.16 Educational content only. Not financial advice.

0 · Reply

EDP554 Aug. 21 at 3:20 PM

$SPRB started a small position here

0 · Reply

MoneyMacG Aug. 20 at 6:07 PM

$COOK $SPRB $EDRY $QNCX gem

0 · Reply

USAEquityResearch Aug. 19 at 11:44 AM

$SPRB 📊 USAEquityResearch ▼ 52.85 (-0.14%) Trend: Bullish 📈 RSI (14): 90.5 — overbought, extended, caution warranted MACD: bullish, above signal line and rising Volume: above average 📌 Key Levels Resistance: 52.92 Support: 41.45 20-MA: 46.08 | 50-MA: 48.78 Educational content only. Not financial advice.

0 · Reply

JeremyDanie Aug. 18 at 1:44 AM

$SPRB hodl

0 · Reply

Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026

2026-08-17T11:05:35.000Z - 7 days ago

Spruce Biosciences price target lowered to $104 from $123 at Guggenheim

2026-08-17T09:40:28.000Z - 7 days ago

Cure Sanfilippo, National MPS agree to make $5.5M investment in Spruce

2026-08-17T09:27:49.000Z - 7 days ago

Spruce Biosciences reports Q2 EPS ($6.68), consensus ($5.93)

2026-08-17T09:27:37.000Z - 7 days ago

Spruce Biosciences sees cash runway into 2H27

2026-08-17T08:29:09.000Z - 7 days ago

Spruce Biosciences price target lowered to $144 from $150 at Citizens

Aug 12, 2026, 9:00 AM EDT - 12 days ago

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Aug 12, 2026, 8:00 AM EDT - 12 days ago

Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences

Aug 12, 2026, 7:00 AM EDT - 12 days ago

Spruce Biosciences Quarterly report: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 12 days ago

Spruce Biosciences Earnings release: Q2 2026

2026-08-03T12:17:20.000Z - 21 days ago

Spruce Biosciences appoints Jessica Cohen Pfeffer as VP, clinical development

BMRN

Aug 3, 2026, 8:00 AM EDT - 21 days ago

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

2026-07-27T12:15:58.000Z - 4 weeks ago

Spruce Biosciences appoints Quartel as Chief Medical Officer

ZVRA

Jul 27, 2026, 8:00 AM EDT - 4 weeks ago

Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer

2026-07-13T12:15:12.000Z - 6 weeks ago

Spruce Biosciences initiated with a Buy at B. Riley

Jul 8, 2026, 4:01 PM EDT - 6 weeks ago

Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

2026-06-29T12:15:24.000Z - 2 months ago

Spruce Biosciences joins Russell 3000 Index

Jun 29, 2026, 8:00 AM EDT - 2 months ago

Spruce Biosciences Joins the Russell 3000® Index

2026-06-22T12:50:27.000Z - 2 months ago

Spruce Biosciences appoints Agnieszka Jurecka as VP, medical affairs

Jun 22, 2026, 8:00 AM EDT - 2 months ago

Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs

2026-06-16T10:46:21.000Z - 2 months ago

Spruce Biosciences initiated with a Buy at Guggenheim

2026-06-15T12:17:18.000Z - 2 months ago

Spruce Biosciences names Eric Jordan VP, marketing, Tina Gullotta VP, finance

BBIO

Jun 15, 2026, 8:00 AM EDT - 2 months ago

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

2026-06-08T20:26:36.000Z - 2 months ago

Spruce Biosciences initiated with a Buy at JonesResearch

2026-06-08T20:11:27.000Z - 2 months ago

Spruce says long-term TA-ERT data presented at MPS Symposium

Jun 8, 2026, 4:05 PM EDT - 2 months ago

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

Jun 4, 2026, 11:05 AM EDT - 2 months ago

Spruce Biosciences Transcript: Jefferies Global Healthcare Conference 2026

2026-06-01T10:11:46.000Z - 3 months ago

Spruce Biosciences price target lowered to $150 from $200 at H.C. Wainwright

May 28, 2026, 4:05 PM EDT - 3 months ago

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

May 27, 2026, 4:05 PM EDT - 3 months ago

Spruce Biosciences to Participate in Upcoming Conferences in June

May 21, 2026, 1:00 PM EDT - 3 months ago

Spruce Biosciences Transcript: AGM 2026

2026-05-14T09:58:05.000Z - 3 months ago

Spruce Biosciences price target lowered to $150 from $170 at Citizens

2026-05-13T16:56:50.000Z - 3 months ago

Spruce Biosciences reports Q1 EPS ($8.94), consensus ($6.11)

May 13, 2026, 8:00 AM EDT - 3 months ago

Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 13, 2026, 8:00 AM EDT - 3 months ago

Spruce Biosciences Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 3 months ago

Spruce Biosciences Quarterly report: Q1 2026

2026-05-04T12:21:00.000Z - 4 months ago

Spruce Biosciences appoints Brian Walls as VP, market access

May 4, 2026, 8:00 AM EDT - 4 months ago

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

Apr 20, 2026, 11:45 PM EDT - 4 months ago

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Apr 20, 2026, 4:01 PM EDT - 4 months ago

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Apr 9, 2026, 8:00 AM EDT - 4 months ago

Spruce Biosciences Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 4 months ago

Spruce Biosciences Proxy statement: Proxy filing

Mar 10, 2026, 12:30 PM EDT - 5 months ago

Spruce Biosciences Transcript: The Citizens Life Sciences Conference 2026

Mar 9, 2026, 11:20 AM EDT - 6 months ago

Spruce Biosciences Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 7:05 AM EDT - 6 months ago

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Mar 9, 2026, 7:00 AM EDT - 6 months ago

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

Mar 9, 2026, 7:00 AM EDT - 6 months ago

Spruce Biosciences Earnings release: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 6 months ago

Spruce Biosciences Annual report: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 6 months ago

Spruce Biosciences Slides: Corporate presentation

Mar 2, 2026, 4:05 PM EST - 6 months ago

Spruce Biosciences to Present at Upcoming Investor Conferences in March

Feb 25, 2026, 3:20 PM EST - 6 months ago

Spruce Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 7:00 AM EST - 6 months ago

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Feb 17, 2026, 4:05 PM EST - 6 months ago

Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 5, 2026, 4:05 PM EST - 7 months ago

Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

Feb 3, 2026, 8:00 AM EST - 7 months ago

Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team

Jan 28, 2026, 8:00 AM EST - 7 months ago

Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™

Jan 18, 2026, 7:02 PM EST - 7 months ago

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

Jan 8, 2026, 8:00 AM EST - 8 months ago

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

Dec 15, 2025, 8:00 AM EST - 9 months ago

Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

Nov 10, 2025, 4:05 PM EST - 10 months ago

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Nov 10, 2025, 7:00 AM EST - 10 months ago

Spruce Biosciences Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 10 months ago

Spruce Biosciences Quarterly report: Q3 2025

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Spruce Biosciences Registration statement: Registration Filing

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Spruce Biosciences Registration statement: Registration Filing

Oct 7, 2025, 9:44 AM EDT - 11 months ago

This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug.

Oct 6, 2025, 8:00 AM EDT - 11 months ago

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Sep 15, 2025, 7:00 AM EDT - 1 year ago

Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

Jyoudoit Aug. 24 at 3:11 PM

$SPRB

0 · Reply

EDP554 Aug. 24 at 1:24 PM

$SPRB adding some more at open

0 · Reply

SannieVerraderlijk Aug. 24 at 12:51 PM

$SPRB Tiny float, 17% short, might run if it catches some volume

0 · Reply

SannieVerraderlijk Aug. 24 at 12:32 PM

0 · Reply

JeremyDanie Aug. 24 at 2:08 AM

$SPRB stop run…and go

0 · Reply

USAEquityResearch Aug. 22 at 6:45 AM

0 · Reply

EDP554 Aug. 21 at 3:20 PM

$SPRB started a small position here

0 · Reply

MoneyMacG Aug. 20 at 6:07 PM

$COOK $SPRB $EDRY $QNCX gem

0 · Reply

USAEquityResearch Aug. 19 at 11:44 AM

0 · Reply

JeremyDanie Aug. 18 at 1:44 AM

$SPRB hodl

0 · Reply

MoneyMacG Aug. 17 at 9:18 PM

$COOK $SPRB $EDRY $INTG ,,

0 · Reply

MoneyMacG Aug. 17 at 7:32 PM

$EDRY $SPRB $INTG $FTH $QNCX gem)))

0 · Reply

1AMBITIOUSSAVAGE Aug. 14 at 11:35 PM

$VSEE just be patient. This company is a potential candidate to be a buyout and have some major news in the pipeline. It’s just a matter of time at this point. Could be a reverse split or a major private buyout like $SPRB had in October 2025. ⏳ LFG Hold Extremely 🔋 🚀

1 · Reply

parbv Aug. 14 at 4:41 PM

$SPRB Good to see that there wasn't any delays in the ER announcement. Going to be worth significantly more if they're able to remain on schedule.

0 · Reply

Quantumup Aug. 13 at 10:18 AM

Citizens⬇️ $SPRB's PT to $144 from $150, reiterated Market Outperform and said: ∘ Pipeline update – SPRB remains on track to submit its BLA for TA-ERT BLA in 4Q26, where we think Priority Review is likely given the high unmet need in MPS IIIB and absence of approved therapies. SPRB expects to start the Transform confirmatory study in 4Q26, a randomized controlled study expected to enroll ~14 severe MPS IIIB patients and will evaluate cognition as the primary endpoint. Additionally, the TA-ERT EAP will start next quarter, which is expected to enroll ~10 U.S. patients who are not eligible for the confirmatory study, providing access to therapy while supporting continued experience with TA-ERT ahead of its potential approval. Here's what Citizens went on to say: https://x.com/Quantumup1/status/2087845923489542207?s=20

0 · Reply

focafoca99 Aug. 12 at 1:23 PM

$SPRB released its Q2 2026 financial results, posted in an 8-K filing.

0 · Reply

Stock_Catcher Aug. 12 at 12:03 PM

$SPRB Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences

0 · Reply

mz08 Aug. 5 at 7:45 AM

$BJDX $GME $AMC $DRUG $SPRB

0 · Reply

IWasWrong Aug. 4 at 3:32 AM

$SPRB I have $20,000 worth in shares. I'm adding more every month

0 · Reply

ShakeThatMoneyMaker Jul. 20 at 3:48 AM

$SPRB if there was options on this trash Id write some 25P for a few months out. This will be sub 35 by the time they get across the finish line as it slowly bleeds out. They diluted way too much and still might again but its still worth a stab after I sold at 52.

2 · Reply

NEWYORKSILVERKING Jul. 16 at 3:10 AM

$SPRB Podcast last month with SPRB CEO..https://empoweredpatientradio.com/enzyme-replacement-therapy-for-sanfilippo-syndrome-type-b-with-dr-javier-szwarcberg-spruce-biosciences?fbclid=IwY2xjawTFKm1leHRuA2FlbQIxMABicmlkETFIa3RySlBXakE3OThyVmgzc3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHqES1j6K0OVzaXUnZu0XD5itBoD8HXSCGbjY47ONwf9QAhwQKy8HkVKBoUY__aem_gjQjSyYUMNw5-fO7_CWp5g

0 · Reply

Heroforest Jul. 15 at 11:37 PM

$SPRB still in the accumulation phase. The price is ugly the ultimate bottom is at 30s… good luck, usually price trend up proceeding the BLA, still 4 months and Half waiting time

0 · Reply

Market Cap	148.24M
Revenue (ttm)	0.00
Net Income (ttm)	-38.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.08

Volume	80,010
Avg Vol	68,312
Day's Range	N/A - N/A
Shares Out	2.87M
Stochastic %K	62%
Beta	3.23
Analysts	Strong Sell
Price Target	$149.71